research Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
Search
forLearn
0 / 0 results — no results
Research
5 / 1000+ results
research Emulgel: A Novel Approach for Hydrophobic Drugs
Emulgels effectively deliver hydrophobic drugs for skin conditions like acne and psoriasis.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Biotechs Target Stagnant Baldness Market
New drug shows promise for better hair growth in baldness treatment.
research Male Pattern Baldness: Causes, Treatments, and Future Prospects
Most American men experience hair loss by age 50, with limited effective treatments available and new options not expected soon.
Community Join
5 / 103 resultscommunity KX-826 Pyrilutamide1% coming soon
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
community Cosmo Pharma 2025 Investor Day Report
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
community Brief update clascoterone phase 3 - Breezula
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
community Binding affinity does not equal potency for anti androgens? Comparing pyrilutimide to cb-03-01
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.